Cyclic AMP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
== See also == List of major Lucha Libre AAA Worldwide events List of AEW PPV events List of ECW supercards and PPV events List of FMW supercards and PPV events List of GFW specials and PPV events List of MLW specials and PPV events List of NWA PPV events List of major NJPW events List of ROH PPV events List of TNA / Impact Wrestling PPV events List of TNA+ Specials List of WCCW supercard events List of WCW closed-circuit events and PPV events List of WCW Clash of the Champions shows List of WWE Saturday Night's Main Event shows List of WWE Tribute to the Troops shows
Skittles are produced in a wide variety of flavors and colors, including sour varieties. Skittles has hinted at new flavor releases on its Facebook page, using such statuses as "Locking myself in the Rainbow kitchen until I see some results!" A 2011 posting contained confirmation of a new flavor: "Putting the last touches on a new Skittles flavor. Tweak the Rainbow." In the United States and Canada, in 2013, Skittles replaced the lime-flavored Skittles with green apple, causing a backlash from many consumers. The lime flavor became part of the Darkside packets, which were discontinued in 2015 and followed up by the Orchards packets, which were discontinued in 2017. Lime was also part of the "Long Lost Lime" packets that came out in summer 2017 and 2018. The Darkside flavor was revived in 2019. In 2021, the "All Lime" packets containing only the lime flavor were released for a limited time. In September 2021, Skittles announced that the green apple-flavored Skittles would be replaced with the original lime flavor. In 2022, Skittles Gummies were released. In October 2024, Skittles released their own version of freeze-dried Skittles called Skittles POP'd. It comes in the Original and Sour Skittles flavors.
CAVE systems included multiple flat screen displays, typically at least three walls to surround the human player, and incorporated some type of tracking sensor system to match the images on the walls to what direction the player was looking. Early applications of CAVE system were game-based demonstrations, but the cost remained prohibitive for commercial deployment even through the 2010s. Around this same time in the 1990s, major innovations in real-time 3D graphics had been made across computer, console, and arcade video games, and with further improvements in affordable consumer technologies, arcade games began to decline as they could not compete with these innovations. Arcade game manufacturers instead focused on offering games that could not easily be replicated at home, which included the introduction of VR-based arcade games. For example, the Virtuality Group produced its Virtuality line of arcade games starting in the early 1990s that typically included a VR headset with head-tracking and other features. However, the cost and upkeep of these machines made it difficult to continue support for them. There remained strong interest from academics to explore what VR, along with augmented reality and other mixed reality systems, could bring to video games, through the 2000s, but these games were mostly prepared for research proof-of-concepts to demonstrate the interaction of VR hardware, software, and human motion rather than for commercial release, since hardware costs were still high.
Sources: en.wikipedia.org
== See also == Chinese herbology Ethnobotany Ethnomedicine Herbal Medicinal fungi List of plants used in herbalism Thomsonianism, a popular 19th century movement Traditional medicine Traditional Knowledge Digital Library
==== United States Champion; departure (1993–1994) ==== At Starrcade '93: 10th Anniversary in December 1993, Austin defeated Dustin Rhodes 2–0 in a two-out-of-three-falls match to win the WCW United States Championship. At Clash of the Champions XXVIII in August 1994, Austin lost the Championship to Ricky Steamboat. He was scheduled to face Steamboat in a rematch at Fall Brawl '94: War Games in September 1994; however, Steamboat was unable to wrestle due to a legitimate back injury and Austin was awarded the championship by forfeit. His second reign with the championship ended just five minutes later when he lost to Steamboat's replacement, Jim Duggan, in a match that lasted 35 seconds. Austin unsuccessful challenged Duggan for the championship at both Halloween Havoc in October 1994 and Clash of the Champions XXIX in November 1994. The influence of Hulk Hogan and the Hulkamania era was beginning to take hold in WCW, with vice president Eric Bischoff saying this was likely the reason Austin lost to Duggan, who had been a popular figure during that period of time. Around this time, Austin pitched a storyline idea to Bischoff in which it would be revealed that Austin was a family member of Hogan. The proposal was quickly turned down on account of Bischoff's belief that Hogan would not work with somebody such as Austin, who was not a proven name. Following Clash of the Champions XXIX, Austin was inactive while rehabilitating a knee injury, returning in February 1995.
Sociologist Robert K. Merton believed deviance depended on society's definition of success, and the desires of individuals to achieve success through socially defined avenues. Criminality becomes attractive when expectations of being able to fulfill goals (therefore achieving success) by legitimate means cannot be fulfilled. Criminal organizations capitalize on states with a lack of norm by imposing criminogenic needs and illicit avenues to achieve them. This has been used as the basis for numerous meta-theories of organized crime through its integration of social learning, cultural deviance, and criminogenic motivations. If crime is seen as a function of anomie, organized behavior produces stability, increases protection or security, and may be directly proportional to market forces as expressed by entrepreneurship- or risk-based approaches. It is the inadequate supply of legitimate opportunities that constrains the ability for the individual to pursue valued societal goals and reduces the likelihood that using legitimate opportunities will enable them to satisfy such goals (due to their position in society).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.